Semaglutide denied as not medically necessary by UnitedHealthcare?

BMI >=30, OR BMI >=27 with at least one weight-related comorbidity (T2DM, hypertension, dyslipidemia, CVD, OSA). 6-month documented diet/exercise program. Step therapy: failed/contraindicated phentermine/topiramate or Contrave trial.

Step-therapy: Document contraindications to required agents - phentermine contraindicated in cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, MAOI use within 14 days (FDA prescribing information); phentermine/topiramate contraindicated in pregnancy, glaucoma, hyperthyroidism, MAOI use (FDA prescribing information); naltrexone/bupropion contraindicated in uncontrolled hypertension, seizure disorders, eating disorders, chronic opioid use, abrupt discontinuation of alcohol/benzodiazepines (FDA prescribing information). If prior trial completed: document inadequate response (weight loss <5% after 12 weeks per 2016 AACE/ACE obesity guidelines) or intolerance with specific adverse effects (e.g., tachycardia, insomnia, nausea, headache). Cite semaglutide 2.4mg FDA approval for chronic weight management in adults with obesity or overweight with weight-related comorbidity (June 2021). Reference STEP 1 trial showing semaglutide produced mean 14.9% body weight reduction vs 2.4% with placebo at 68 weeks (NEJM 2021;384:989-1002). Cite AMA recognition of obesity as a disease requiring treatment (2013) and 2016 AACE/ACE obesity algorithm supporting GLP-1 receptor agonists when lifestyle and first-line pharmacotherapy fail or are contraindicated. BMI threshold: Verify FDA indication (BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia). Supervised program: Document prior lifestyle intervention attempts including dietary counseling and increased physical activity per FDA indication requirements. Employer carve-out: Request plan documents confirming exclusion; appeal as medically necessary treatment for chronic disease; consider state parity laws if applicable.

UnitedHealthcare denies semaglutide for medical necessity most often when the BMI documentation is buried in the chart or when the comorbidity isn't explicitly framed as weight-driven. UHC reviewers — typically OptumRx pharmacists with structured criteria — don't infer; they look for each policy element satisfied verbatim in the documentation in front of them.

The appeal letter has to make every UHC criterion explicit and quoted from the chart:

• BMI ≥30, or ≥27 with weight-related comorbidity — give the exact BMI from a recent visit (within 12 months), not a range. If between 27-29.9, the comorbidity must be a weight-driven diagnosis, not just co-existing.
• Comorbidity framed as weight-driven — UHC weights this more than most plans. "Hypertension" alone in the problem list gets denied at BMI 28; "obesity-associated hypertension responsive to weight loss" in a recent prescriber note gets approved. Phrase the comorbidity as weight-driven, never just co-existing.
• 6-month documented diet/exercise program — give specific dates, the program name (Noom Med, WeightWatchers Clinical, Form Health, hospital-based program), and what was tried (calorie target, exercise prescription, behavioral intervention).
• Step therapy or contraindication — either dates of phentermine/topiramate or Contrave trial with documented response, OR a chart-cited contraindication. UHC accepts contraindications without requiring an adequate-dose failure: uncontrolled hypertension on phentermine, prior cardiovascular event ruling out stimulants, glaucoma, MAO-inhibitor use, severe anxiety on prior trial.
• Side-effect contraindications — if the patient stopped phentermine due to anxiety or insomnia, frame as contraindication, not "didn't tolerate." Many appeals get re-denied because they describe a side effect rather than naming it as a contraindication and citing the specific visit where it was documented.

The federal hook: medical-necessity denials are coverage determinations subject to ERISA §503 and 29 CFR §2560.503-1, requiring a full review by a clinically qualified reviewer with the same training as the prescribing specialist. UHC's denial letter must name the reviewer and the reviewer's specialty; if it doesn't, request that information explicitly under 29 CFR §2560.503-1(g)(1)(iv) — unnamed reviewers are a procedural defect supporting the appeal.

OptumRx-specific procedural lever: cite the OptumRx GLP-1 PA Guideline version date in the appeal. OptumRx revises criteria periodically; reviewers sometimes apply older policy language. Confirming the current version forces them to use current criteria.

Closing tactical tip: request a peer-to-peer review with an endocrinologist or obesity medicine specialist before submitting the formal appeal — UHC's specialty-matched reviewers overturn at materially higher rates than generalist reviewers.